Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 3/20 | 0.46 |
| ▸ | HTR1B | P28222 | 7/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6538470 | 0.83 | HTR1B (0.53) | KCNA3HTR1BSLC6A4HRH1TDP1 | |
| SCHEMBL4720961 | 0.81 | ALDH1A1 (0.33) | MEN1KMT2A | |
| SCHEMBL6538521 | 0.77 | KCNA3 (0.52) | KCNA3HTR1B | |
| SCHEMBL9421991 | 0.75 | KCNA3 (0.54) | KCNA3HTR1BSLC6A4HRH1HTR1D | |
| SCHEMBL1396371 | 0.75 | LTA4H (0.41) | TDP1MEN1KMT2A | |
| SCHEMBL28411404 | 0.75 | HTR1B (0.54) | KCNA3HTR1BSLC6A4HRH1TDP1 | |
| SCHEMBL2458064 | 0.74 | MCHR1 (0.41) | SLC6A4HRH1TDP1HRH3HTR2A | |
| SCHEMBL6283599 | 0.74 | MCHR1 (0.41) | SLC6A4HRH1TDP1HRH3HTR2A | |
| SCHEMBL20678360 | 0.74 | KCNA3 (0.53) | KCNA3HTR1BSLC6A4HRH1HTR1D | |
| SCHEMBL17912877 | 0.74 | KCNA3 (0.53) | KCNA3HTR1BSLC6A4HRH1HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743776-B2 | ANTIFUNGAL, BETA-1,3-GLUCAN SYNTHASE INHIBITOR, PNEUMOCYSTIS CARINII; AMIDATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-0941236-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998023637-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | NGLY1, CHIT1, MANBA | KCNA3 2839/4885HTR1B 4040/4885SLC6A4 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.